GSK plc’s Regenxbio RGNX Stock Holding History

GSK plc’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.25M	Hold	271,456	–	–	0.54%	13
2026 Q1	$2.27M	Hold	271,456	–	–	0.38%	13
2025 Q4	$3.91M	Buy	+271,456	New	+$3.38M	0.49%	13

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GSK plc's RGNX Position: Q2 2026 in Review

GSK plc held its Regenxbio (RGNX) position steady in Q2 2026 at 271,456 shares worth $3.25M. The position accounts for 0.54% of the portfolio, ranked #13.

GSK plc first reported a position in RGNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.91M in Q4 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

GSK plc held 271,456 shares of Regenxbio worth $3.25M as of Q2 2026.
GSK plc left its Regenxbio share count unchanged in Q2 2026.
Regenxbio made up 0.54% of GSK plc's portfolio in Q2 2026, its #13 holding.
GSK plc first reported a position in Regenxbio in Q4 2025 and has held it in 3 quarters since.
GSK plc's Regenxbio position peaked at $3.91M in Q4 2025.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.